Abstract
The aim of this study was to verify the efficacy of a modified Odkvist titration protocol of intratympanic gentamicin application in the control of vertigo attacks and the effects on the auditory and vestibular function in a group of 71 patients affected by monolateral MD resistant to medical therapy. All the patients underwent an intratympanic administration of a 1-ml solution containing 26.6 mg of gentamicin sulfate. The treatment protocol provided one to three injections for a total amount of gentamicin varying from 26.6 to 80 mg. Five days after the first gentamicin administration, cochlear and vestibular function tests were performed. The worsening of the PTA greater than 15 dB, the appearance of clinical signs of vestibulotoxicity such as imbalance or persistent spontaneous nystagmus beating away from the injected ear or of a “curative vertigo” were the criteria taken into consideration to stop the treatment. In the absence of any sign, a second and third injection were performed. The presence of an unchanged frequency of the attacks at least 3 months after the previous cycle was the parameter considered to perform a second or third cycle. Seventeen (24%) patients were submitted to a second cycle of therapy and two (3%) to a third cycle. After a mean follow-up period of 20.3 months (range: 3 to 48) all 71 patients experienced good control of the vertigo attacks: grade A in 46 cases and grade B in 25 cases according to the AAO-HNS CoHE criteria. The pure tone average (PTA) hearing threshold (500–3,000 Hz) worsened in 19 patients, improved in 5 and was unchanged in 47. On the basis of the experience acquired during the treatment, we progressively decreased the number of injections from 3/cycle to a 1–2/cycle of therapy. Moreover, in the later phase of the study re-injections were administered 1 or 2 weeks after the previous application and avoided in the presence of signs of depression of the vestibular and/or cochlear function. A residual caloric excitability was found in 30% of the cases. Vertigo control doesn’t seem to be linked to the achievement of vestibular inexcitability. The marker of successful gentamicin treatment at short-term is the appearance of signs of curative vertigo and/or vestibular imbalance, and at long-term the disappearance of vertigo attacks.
Similar content being viewed by others
References
Aran JM, Dulon D, Hiel H, Erre JP, Aurousseau C (1993) L’ototoxicité d’aminoglicosides: résultats récents sur la captation et la clairance de la gentamicine par les cellules sensorielles du limacon osseux. Rev Laryngol Otol Rhinol (Bord) 114:125–128
Atlas JT, Parnes LS (1999) Intratympanic gentamicin titration therapy for intractable Meniere’s disease. Am J Otol 20:257–263
Beck C, Schimdt CL (1978) Ten years experience with intratympanically applied streptomycin (gentamicin) in the therapy of morbus Meniere. Arch Otorhinolaryngol 221:149–152
Black FO, Pesznecker S, Stallings V (2004) Permanent gentamicin vestibulotoxicity. Otol Neurotol 25:559–569
Blakley BW (2000) Update of intratympanic gentamicin for Meniere’s disease. Laryngoscope 110:236–240
Chia SH, Gamst AC, Anderson JP, Harris JP (2004) Intratympanic gentamicin therapy for Meniere’s disease: a meta-analysis. Otol Neurotol 25:544–552
Committee on Hearing and Equilibrium of the American Academy of Otolaryngology Head and Neck Surgery (1995) Committee on hearing and equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. Otolaryngol Head Neck Surg 113:181–185
Conlon BJ, Gibson PR (1999) Meniere’s disease: the incidence of hydrops in the controlateral asymptomatic ear. Laryngoscope 109:1800–1802
Driscoll CLW, Kasperbauer JL, Facer GW, Harner SG (1997) Low-dose intratympanic gentamicin and the treatment of Meniere’s disease: preliminary results. Laryngoscope 107:83–89
Fowler E (1948) Streptomycin treatment of vertigo. Trans Am Acad Ophtalmol Otolaryngol 52:239–301
Harner SG, Driscoll CLW, Facer GW, Beatty CW, McDonald TJ (2001) Long-term follow-up of transtympanic gentamicin for Menière’s syndrome. Otol Neurotol 22:210–214
Hirsch BE, Kamerer DB (1997) Intratympanic gentamicin therapy for Meniere’s disease. Am J Otol 18:44–51
Hoffman F, Beck, C Beck C, Stratulat S (1993) Subablative gentamicin therapy in Meniere’s disease. HNO 41:296–300
Kaplan DM, Nedzelski JM, Chen JM, Shipp DB (2000) Intratympanic gentamicin for the treatment of unilateral Meniere’s disease. Laryngoscope 110:1298–1305
Kumar A (1981) Diagnostic advantages of the Torok monothermal differential caloric test. Laryngoscope 91:1678–1694
Lange G, Maurer J, Mann W (2004) Long-term results after interval therapy with intratympanic gentamicin for Meniere’s disease. Laryngoscope 114:102–105
Leone CA, Mosca F, Mincione A (2000) La terapia ablativa con gentamicina nel trattamento della malattia di Menière. Acta Otorhinolaryngol Ital 20:322–329
Longridge NS, Mallison AI (2000) Low-dose intratympanic treatment for dizziness in Meniere’s disease. J Otolaryngol 29:35–39
Lundquist PG, Wersall J (1967) The ototoxic effect of gentamicin—an electron microscopic study. In: Gentamicin. First International Symposium. Schwabe, Basel, pp 26–46
Magnusson M, Padoan S (1991) Delayed onset of ototoxic effects of gentamicin in treatment of Meniere’s disease. Rationale for extremely low dose therapy. Acta Otolaryngol (Stockh) 111:671–676
Minor LB (1999) Intratympanic gentamicin for control of vertigo in Meniere’s disease: vestibular signs that specify completion of therapy. Am J Otol 20:209–219
Nedzelski JM, Bryce GE, Pfleiderer AG (1992) Treatment of Meniere’s disease with topical gentamicin: a preliminary report. J Otolaryngol 21:95–101
Odkvist LM, Bergholtz LM, Lundgren A (1984) Topical gentamicin treatment for disabling Meniere’s disease. Acta Otolaryngol (Stockh) [Suppl] 412:74–76
Pender D (1985) Gentamicin tympanoclisis: effects on the vestibulary secretory cells. Am J Otolaryngol 6:358–367
Quaranta A, Scaringi A, Aloisi A, Quaranta N, Salonna I (2001) Intratympanic therapy for Meniere’s disease: effect of administration of low concentration of gentamicin. Acta Otolaryngol (Stockh) 121:387–392
Rudnick MD, Ginsberg IA, Huber PS (1980) Aminoglycoside ototoxicity following middle ear injection. Ann Otol Rhinol Laryngol 89 [Suppl 779]:1–9
Rybak LP (1986) Ototoxic mechanism. Neurobiology of hearing. Raven Press, New York, pp 441–454
Schuknecht HF (1957) Ablation therapy in the management of Meniere’s disease. Acta Otolaryngol (Stockh) [Suppl] 132:1–42
Stokroos R, Kingma H (2004) Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Meniere’s disease: a prospective, double blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol (Stockh) 124:172–175
Thai-Van H, Bounaix MJ, Fraysse B (2001) Meniere’s disease. Pathophisiology and treatment. Drugs 61:1089–1102
Tran Ba Huy P, Bernard P, Schacht J (1986) Kinetics of gentamicin uptake and release in the rat: comparison of inner ear tissue and fluids with other organs. J Clin Invest 77:1492–1500
Williams SE, Zenner H, Schacht J (1987) Three molecular steps of aminoglycoside ototoxicity demonstrated in outer hair cells. Hear Res 30:11–18
Youssef TF, Poe DS (1998) Intratympanic gentamicin injection for the treatment of the Meniere’s disease. Am J Otol 19:435–442
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bertino, G., Durso, D., Manfrin, M. et al. Intratympanic gentamicin in monolateral Meniere’s disease: our experience. Eur Arch Otorhinolaryngol 263, 271–275 (2006). https://doi.org/10.1007/s00405-005-0988-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-005-0988-0